Meanwhile, anti-VEGF monoclonal antibodies can enhance T-cell-mediated tumor cell killing effect of immune checkpoint inhibitors such as anti-PD-1/CTLA-4 by promoting tumor vascular normalization, reversing VEGF-mediated tumor immunosuppression, and down-regulating MDSCs and Treg to regulate the tumor immune microenvironment. This evidence concerns the gene CTLA4 and neoplasm.